NCT05001828 2026-01-21
Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia
Polaris Group
Phase 1 Active not recruiting
Clinical Trials
16 trialsNCT05317819 2025-12-18
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Phase 3 Recruiting
NCT04587830 2025-08-26
GBM
Polaris Group
Phase 2 Active not recruiting
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT03254732 2022-04-27
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
Polaris Group
Phase 1 Terminated
NCT02102022 2022-04-25
Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma
Polaris Group
Phase 1/2 Terminated
NCT01910012 2020-10-01
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Polaris Group
Phase 2 Completed
NCT02101580 2020-10-01
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Polaris Group
Phase 1 Completed
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT02875093 2020-03-05
Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML
Polaris Group
Phase 1 Terminated
NCT01287585 2019-09-06
ADI-PEG 20
Polaris Group
Phase 3 Completed
NCT01910025 2018-09-18
PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy
Polaris Group
Phase 2 Completed
NCT02006030 2018-09-04
TACE
Polaris Group
Phase 2 Completed
NCT01948843 2016-04-14
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Polaris Group
Phase 1 Completed
NCT02101593 2016-03-04
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Polaris Group
Phase 1 Completed
NCT01665183 2016-02-25
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Polaris Group
Phase 1 Completed